Patents Examined by Margaret Parr
  • Patent number: 5595880
    Abstract: The present invention provides an isolated nucleic acid molecule encoding an .alpha..sub.2B -adrenergic receptor, and an isolated protein which is a human .alpha..sub.2B -adrenergic receptor. The invention also provides vectors comprising DNA molecules encoding a human .alpha..sub.2B -adrenergic receptor, and vectors adapted for expression of the .alpha.2b.sub.2B -adrenergic receptor in bacterial, yeast, or mammalian cells. In addition, the invention provides a DNA probe useful for detecting nucleic acid encoding the .alpha.2b.sub.2B -adrenergic receptor, a method for determining whether a ligand which is not known to be capable of binding to the .alpha.2b.sub.2B -adrenergic receptor can bind to the .alpha..sub.2B -adrenergic receptor on the surface of a cell, and a method of screening drugs to identify drugs to identify drugs which specifically interact with, and bind to, the .alpha..sub.2B -adrenergic receptor. The invention herein also concern an antibody directed to the human .alpha..sub.
    Type: Grant
    Filed: October 22, 1992
    Date of Patent: January 21, 1997
    Assignee: Synaptic Pharmaceutical Corporation
    Inventors: Richard L. Weinshank, Paul R. Hartig
  • Patent number: 5593828
    Abstract: A new and improved polymeric membrane for use in biological assays is provided. A blotting assay employing 1,2-dioxetanes as a source of chemiluminescent employs, as an improved membrane, a polymer comprised of at least one monomer of the formula: ##STR1## The membranes reduce background signal, improve sensitivity and reliability.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: January 14, 1997
  • Patent number: 5591838
    Abstract: Compositions and methods for detecting the conversion to mucoidy in Pseudomonas aeruginosa are disclosed. Chronic respiratory infections with mucoid Pseudomonas aeruginosa are the leading cause of high mortality and morbidity in cystic fibrosis. The initially colonizing strains are nonmucoid but in the cystic fibrosis lung they invariably convert into the mucoid form causing further disease deterioration and poor prognosis. The molecular basis of this conversion to mucoidy is also disclosed. The algU gene encodes a protein homologous to an alternative sigma factor regulating sporulation and other developmental processes in Bacillus, and along with the negative regulators mucA and mucB comprises the gene cluster controlling conversion to mucoidy. The switch from nonmucoid to mucoid state is caused by frameshift deletions and duplications in the second gene of the cluster, mucA. Inactivation of mucA results in constitutive expression of genes, such as algD, dependent on algU for transcription.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: January 7, 1997
    Assignee: Board of Regents, The University of Texas System
    Inventors: Vojo Deretic, Daniel W. Martin
  • Patent number: 5580780
    Abstract: A novel endothelial cell molecule, VAP-1, is described that mediates lymphocyte binding in man. Further described are anti-VAP-1 monoclonal antibodies and methods for the diagnosis and treatment of inflammatory and autoimmune diseases by the administration of VAP-1 binding compounds, such as anti-VAP-1 antibodies.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: December 3, 1996
    Inventors: Sirpa Jalkanen, Marko Salmi
  • Patent number: 5578704
    Abstract: Hybridoma cell line, ATCC HB 11029, which produces murine monoclonal antibody, 10C4.1.3 which specifically binds to alphavbeta3 integrin on human osteoclasts, and is capable of blocking binding of alphavbeta3 integrin to fibrinogen or to vitronectin. The antibody is useful for detecting alphavbeta3 integrin on cells in histological and diagnostic assays, and to treat disease conditions that are characterized by excessive bone resorption.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: November 26, 1996
    Assignee: Genentech, Inc.
    Inventors: Kyung J. Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 5569601
    Abstract: The present invention is directed toward the isolation, characterization and pharmacological use of the human D4 dopamine receptor. The nucleotide sequence of the gene corresponding to this receptor and alleleic variant thereof are provided by the invention. The invention also includes recombinant eukaryotic expression constructs capable of expressing the human D4 dopamine receptor in cultures of transformed eukaryotic cells. The invention provides cultures of transformed eukaryotic cells which synthesize the human D4 dopamine receptor, and methods for characterizing novel psychotropic compounds using such cultures.
    Type: Grant
    Filed: August 10, 1992
    Date of Patent: October 29, 1996
    Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on Behalf of the Oregon Health Sciences University
    Inventor: Olivier Civelli
  • Patent number: 5569602
    Abstract: The present invention is related to immortalized cell lines. More particularly, the present invention is related to an immortalized Kaposi's sarcoma (KS) cell line derived from cells isolated from the pleural effusion of AIDS patients with KS. Monoclonal antibodies against KS cells are also provided, as are methods for evaluating antimalignancy therapies.
    Type: Grant
    Filed: August 20, 1993
    Date of Patent: October 29, 1996
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Yanto Lunardi-Iskandar, Robert C. Gallo
  • Patent number: 5565550
    Abstract: The present invention relates to intercellular adhesion molecules (ICAM-2) which are involved in the process through which lymphocytes recognize and migrate to sites of inflammation as well as attach to cellular substrates during inflammation. The invention is directed toward such molecules, screening assays for identifying such molecules and antibodies capable of binding such molecules. The invention also includes uses for adhesion molecules and for the antibodies that are capable of binding them.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: October 15, 1996
    Assignee: Dana Farber Cancer Institute
    Inventors: Timothy A. Springer, Donald E. Staunton, Michael L. Dustin
  • Patent number: 5565321
    Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating a syndrome that results in elevated levels of serum IgM and diminished levels of all other isotypes of immunoglobulins are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: October 15, 1996
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III
  • Patent number: 5558989
    Abstract: The present invention relates to a method of selectively detecting Giardia lamblia in a sample. The method makes use of at least one nucleic acid probe which is a DNA or PNA sequence which hybridizes, under appropriate conditions, to the ribosomal RNA or the ribosomal DNA of Giardia lamblia but does not hybridize to the ribosomal RNA or the ribosomal DNA of other organisms (non-Giardia lamblia organisms) which may be present in a sample.
    Type: Grant
    Filed: May 9, 1994
    Date of Patent: September 24, 1996
    Assignee: Amoco Corporation
    Inventors: Jyotsna S. Shah, Amelia Buharin, David J. Lane
  • Patent number: 5558852
    Abstract: Methods of treating solid or cystic tumors are disclosed. The method comprises administering to a human subject afflicted with a tumor an antibody in a therapeutically effective amount, wherein the antibody is monoclonal antibody Me1-14 or an antibody which binds to the epitope bound by monoclonal antibody Me1-14, and wherein the Fc receptor of the antibody is deleted. When the tumor is a brain tumor, the antibody may be administered by intrathecal injection. If the brain tumor is a cystic brain tumor, and the administering step may be carried out by depositing the antibody in the cyst cavity of the cystic brain tumor. Particularly preferred is a monoclonal antibody Me1-14 F(ab').sub.2 fragment coupled to .sup.131 I.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: September 24, 1996
    Assignee: Duke University
    Inventors: Darell D. Bigner, Michael R. Zalutsky
  • Patent number: 5556947
    Abstract: This invention provides an IL-6 dependent B-cell lymphoma cell line designated DS-1 deposited with the American Type Culture Collection, wherein the cell line is reactive with a monoclonal antibody produced by a hybridoma cell line designated 10D2F6 deposited with the American Type Culture Collection. The invention also provides a purified antigen reactive with a monoclonal antibody produced by 10D2F6. The antigen also exists on DS-1. Also provided is a method of detecting the presence of an antigen-stimulated T-cell comprising detecting the presence of the antigen on a lymphocyte. In addition, the invention provides a method of detecting the presence of a neoplastic cell comprising detecting the presence of the antigen on a cell which is not normal a T-cell.
    Type: Grant
    Filed: August 9, 1994
    Date of Patent: September 17, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Glenn H. Bock, David L. Nelson, Carole C. Kurman, Thomas A. Fleisher
  • Patent number: 5556762
    Abstract: Synthetic peptide combinatorial libraries (sets) having a single, predetermined amino acid residue at a single, predetermined oligopeptide chain position and mixtures of amino acid residues at the other chain positions are disclosed, as are their processes of synthesis and use in determining the amino acid residue sequence of an oligopeptide ligand that binds to an acceptor molecule.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: September 17, 1996
    Assignee: Houghten Pharmaceutical Inc.
    Inventors: Clemencia Pinilla, Jon R. Appel, Jr., Richard A. Houghten
  • Patent number: 5556757
    Abstract: Peptides comprising a Meningitis Related Homologous Antigenic Sequence (MRHAS) are provided. The MRHAS is found in meningitis-causing organisms and chemokines involved in cell chemotaxis. The peptides are useful as antigens and vaccines for detection, diagnosis and treatment of meningitis.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 17, 1996
    Assignee: Insight Biotek, Inc.
    Inventors: Diane V. Alstyne, Lawrence R. Sharma
  • Patent number: 5556758
    Abstract: A highly sensitive chemiluminescent indicator system is disclosed for determining the presence or amount of an analyte in a liquid sample. The new acid optimum chemiluminescent indicator system comprises haloperoxidase (halide:hydrogen peroxide oxidoreductase), halide, oxidant and chemiluminigenic substrate. The indicator system acts as a synthesizer of highly reactive singlet molecular oxygen (.sup.1 O.sub.2), which reacts with the chemiluminigenic substrate to yield an excited state, oxidized reaction product. The excited state reaction product then relaxes to a lower energy (e.g., ground) state with the emission of measurable light in an amount related to the amount of each of the reaction participants present in a reaction solution. Known, non-rate limiting amounts of three of the reaction participants are provided in an assay solution to determine the presence or amount of the fourth participant in a test sample.
    Type: Grant
    Filed: May 19, 1994
    Date of Patent: September 17, 1996
    Assignee: ExOxEmis, Inc.
    Inventor: Robert C. Allen
  • Patent number: 5550018
    Abstract: The present invention comprises the method of evaluation of the safety of live attenuated vaccines based on detection and measurement of the incidence of genetic changes associated with reversion to virulence in vaccine microorganisms. The method based on PCR and restriction enzyme analysis was developed and used for determination of the proportion of mutants contributing to neurovirulence of type 3 live oral poliovirus vaccine. The correlation between the neurovirulence of OPV lots revealed by the monkey test and the abundance of mutant virus containing cytidine in the position 472 was discovered. The amount of these mutants increases upon passages of the virus in cell cultures at a rate dependent on the cell type, cultivation conditions and the seed virus stock.
    Type: Grant
    Filed: May 18, 1994
    Date of Patent: August 27, 1996
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Inessa Levenbook, Konstantin Chumakov, Laurie Powers, Igor Roninson
  • Patent number: 5549882
    Abstract: A method for imaging foci of infection by administering radiolabeled human IgM 16.88.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: August 27, 1996
    Assignee: Akzo Nobel N.V.
    Inventor: Ramaswamy Subramanian
  • Patent number: 5548065
    Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1a (murine flk-2), FIG. 1b (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1a, FIG. 1b and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.
    Type: Grant
    Filed: October 31, 1994
    Date of Patent: August 20, 1996
    Assignee: The Trustees of Princeton University
    Inventor: Ihor R. Lemischka
  • Patent number: 5545405
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: August 13, 1996
    Assignee: Burroughs Wellcome Co.
    Inventor: Martin J. Page
  • Patent number: 5545404
    Abstract: The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
    Type: Grant
    Filed: November 3, 1994
    Date of Patent: August 13, 1996
    Assignee: Burroughs Wellcome Co.
    Inventor: Martin J. Page